STOCK TITAN

Biogen Inc - BIIB STOCK NEWS

Welcome to our dedicated news page for Biogen (Ticker: BIIB), a resource for investors and traders seeking the latest updates and insights on Biogen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biogen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biogen's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
-
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
-
Biogen Inc

Nasdaq:BIIB

BIIB Rankings

BIIB Stock Data

28.37B
144.82M
0.69%
92.98%
2.44%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About BIIB

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili